Medpace (MEDP) Financial Analysis & Valuation | Quarter Chart
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical... more
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $17.42B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Medical - Diagnostics & Research |
| Country | US | CEO | August James Troendle |
| IPO Date | 2016-08-11 | CAGR | 20.39% |
| Employees | 6,500 | Website | www.medpace.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 3.2% | Total Yield | 3.2% |
MEDP chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $14.73B | P/E | 36.59 | Forward P/E | 32.32 | PEG | 0.99 |
| P/S | 3.32 | P/B | 21.1 | P/CF | 12.17 | P/FCF | 12.07 |
| Sales | $2.78B | Sales 1Y | 24.67% | Sales 3Y | 66.33% | Sales 5Y | 170.57% |
| EPS | $17.06 | EPS 1Y | 26.91% | EPS 3Y | 104.19% | EPS 5Y | 268.68% |
| Sales QoQ | 0.1% | EPS QoQ | -0.7% | Sales QoQ Avg | 4.14% | EPS QoQ Avg | 9.11% |
| Gross Margin | 28.76% | Operating Margin | 20.97% | Profit Margin | 17.67% | ROCE | 93.83% |
| ROA | 24% | ROE | 110% | Altman Z Score | 8.16 | Piotroski Score | 7 |
| Current Ratio | 0.73 | Quick Ratio | 0.73 | Cash Ratio | 0.35 | Op. CF Ratio | 0.11 |
| Debt/Equity | 0.28 | Debt/Assets | 0.06 | Lt Debt/Equity | 0.55 | Lt Debt/Cap. | 0.22 |
| Intrst Cov. | — | Inventory Turnover | — | Asset Turnover | 1.35 | Receivables Turnover | 6.3 |
| Enterprise Value | $14.73B | P/E Ratio | 36.59 |
| Forward P/E | 32.32 | PEG Ratio | 0.99 |
| P/S Ratio | 3.32 | P/B Ratio | 21.1 |
| P/CF Ratio | 12.17 | P/FCF Ratio | 12.07 |
| EPS | $17.06 | EPS Growth 1Y | 26.91% |
| EPS Growth 3Y | 104.19% | EPS Growth 5Y | 268.68% |
| Revenue Growth 1Y | 24.67% | Gross Margin | 28.76% |
| Operating Margin | 20.97% | Profit Margin | 17.67% |
| ROE | 110% | ROA | 24% |
| ROCE | 93.83% | Current Ratio | 0.73 |
| Quick Ratio | 0.73 | Cash Ratio | 0.35 |
| Debt/Equity | 0.28 | Interest Coverage | — |
| Altman Z Score | 8.16 | Piotroski Score | 7 |
Medpace (MEDP) valuation & financials
Medpace (MEDP) has a market capitalization of $17.42B and trades at a price-to-earnings ratio of 36.6. It operates in the Healthcare sector (Medical - Diagnostics & Research).
Medpace's revenue grew +24.7% over the last year.
Medpace's next earnings report is scheduled for October 28, 2026 after market close (provider scheduled date); analysts estimate EPS of $4.45. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)